NCT03273842View on ClinicalTrials.gov

A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

422

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

July 25, 2018

Study Completion Date

July 25, 2018

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

PF-06881894

pre-filled syringe 6 mg

BIOLOGICAL

US-approved Neulasta

pre-filled syringe 6 mg

Trial Locations (4)

32256

Quotient Sciences- Jacksonville, LLC, Jacksonville

33126

Seaview A Quotient Clinical Business, Miami

33134

Seaview A Quotient Clinical Business, Coral Gables

66212

Vince & Associates Clinical Research Inc., Overland Park

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03273842 - A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers | Biotech Hunter | Biotech Hunter